ANTHRACYCLINE-INDUCED CARDIOTOXICITY
Clinical trials for ANTHRACYCLINE-INDUCED CARDIOTOXICITY explained in plain language.
Never miss a new study
Get alerted when new ANTHRACYCLINE-INDUCED CARDIOTOXICITY trials appear
Sign up with your email to follow new studies for ANTHRACYCLINE-INDUCED CARDIOTOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart shield: cholesterol drug may prevent Chemo-Induced cardiac damage
Prevention Not yet recruitingThis study tests whether rosuvastatin, a cholesterol-lowering drug, can prevent heart damage in women with breast cancer receiving anthracycline chemotherapy. 400 participants will take either rosuvastatin or a placebo daily for 12 months. The main goal is to see if the drug help…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIOTOXICITY
Phase: PHASE4 • Sponsor: Shiraz University of Medical Sciences • Aim: Prevention
Last updated May 17, 2026 08:18 UTC
-
Heart shield: new trial tests drug to stop chemo side effects
Prevention Not yet recruitingThis study tests whether a drug called sotagliflozin can prevent heart, muscle, and fat damage caused by a common type of chemotherapy (anthracycline) in people with newly diagnosed lymphoma. About 60 adults will receive either the drug or a placebo during their first round of ch…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIOTOXICITY
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Prevention
Last updated May 17, 2026 08:18 UTC